Martha E. Lopez

1.3k total citations
19 papers, 1.1k citations indexed

About

Martha E. Lopez is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Martha E. Lopez has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Cell Biology. Recurrent topics in Martha E. Lopez's work include Fibroblast Growth Factor Research (7 papers), Glycosylation and Glycoproteins Research (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Martha E. Lopez is often cited by papers focused on Fibroblast Growth Factor Research (7 papers), Glycosylation and Glycoproteins Research (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Martha E. Lopez collaborates with scholars based in United States, Germany and Switzerland. Martha E. Lopez's co-authors include Murray Korc, Helmut Friess, Markus W. Büchler, Yoichiro Yamanaka, Michael S. Kobrin, Helmut Frieß, Markus Wagner, Toshiyuki Ishiwata, Alison L. Young and Arthur D. Lander and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Gastroenterology.

In The Last Decade

Martha E. Lopez

19 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martha E. Lopez United States 15 768 540 240 162 127 19 1.1k
M Terada Japan 12 757 1.0× 365 0.7× 157 0.7× 102 0.6× 90 0.7× 15 1.0k
Eva Cubillo Spain 9 794 1.0× 528 1.0× 259 1.1× 109 0.7× 58 0.5× 10 1.1k
Takashi Sugimura Japan 11 740 1.0× 262 0.5× 179 0.7× 164 1.0× 97 0.8× 11 949
Yanli Su United States 15 790 1.0× 472 0.9× 303 1.3× 159 1.0× 127 1.0× 22 1.4k
Ivan Ischenko Germany 19 621 0.8× 507 0.9× 269 1.1× 80 0.5× 168 1.3× 22 1.2k
Surabhi Dangi‐Garimella United States 14 749 1.0× 673 1.2× 426 1.8× 120 0.7× 146 1.1× 34 1.4k
Mary Thorncroft United Kingdom 18 807 1.1× 654 1.2× 322 1.3× 51 0.3× 136 1.1× 24 1.2k
Lidia Moserle Italy 18 647 0.8× 496 0.9× 341 1.4× 63 0.4× 158 1.2× 26 1.1k
Maher N. Younes United States 19 517 0.7× 498 0.9× 169 0.7× 49 0.3× 95 0.7× 21 1.1k
Angela A.G. van Tilborg Netherlands 15 690 0.9× 305 0.6× 201 0.8× 122 0.8× 266 2.1× 23 1.1k

Countries citing papers authored by Martha E. Lopez

Since Specialization
Citations

This map shows the geographic impact of Martha E. Lopez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martha E. Lopez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martha E. Lopez more than expected).

Fields of papers citing papers by Martha E. Lopez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martha E. Lopez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martha E. Lopez. The network helps show where Martha E. Lopez may publish in the future.

Co-authorship network of co-authors of Martha E. Lopez

This figure shows the co-authorship network connecting the top 25 collaborators of Martha E. Lopez. A scholar is included among the top collaborators of Martha E. Lopez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martha E. Lopez. Martha E. Lopez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Aikawa, Takuma, Chery A. Whipple, Martha E. Lopez, et al.. (2008). Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. Journal of Clinical Investigation. 118(1). 89–99. 145 indexed citations
2.
Lopez, Martha E., et al.. (2004). Use of cytological specimens for p53 gene alteration detection in oral squamous cell carcinoma risk patients. Clinical Oncology. 16(5). 366–370. 14 indexed citations
3.
Lopez, Martha E., et al.. (2003). Gene promoter hypermethylation in oral rinses of leukoplakia patients—a diagnostic and/or prognostic tool?. European Journal of Cancer. 39(16). 2306–2309. 59 indexed citations
4.
Kornmann, Marko, Toshiyuki Ishiwata, Kei Matsuda, et al.. (2002). IIIc isoform of fibroblast growth factor receptor 1 is overexpressed in human pancreatic cancer and enhances tumorigenicity of hamster ductal cells. Gastroenterology. 123(1). 301–313. 34 indexed citations
5.
Kleeff, Jörg, Martha E. Lopez, Helmut Frieß, et al.. (2002). Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Therapy. 9(6). 522–532. 25 indexed citations
6.
Kornmann, Marko, Martha E. Lopez, H. G. Beger, & Murray Korc. (2001). Expression of the IIIc Variant of FGF Receptor-1 Confers Mitogenic Responsiveness to Heparin and FGF-5 in TAKA-1 Pancreatic Ductal Cells. International Journal of Gastrointestinal Cancer. 29(2). 85–92. 19 indexed citations
7.
Lopez, Martha E., et al.. (2001). p53, un gen supresor tumoral. 98(1). 21–27. 2 indexed citations
8.
Lopez, Martha E. & Murray Korc. (2000). A Novel Type I Fibroblast Growth Factor Receptor Activates Mitogenic Signaling in the Absence of Detectable Tyrosine Phosphorylation of FRS2. Journal of Biological Chemistry. 275(21). 15933–15939. 11 indexed citations
9.
Wagner, Markus, et al.. (1998). Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer growth in vitro and in vivo. Gastroenterology. 114(4). 798–807. 59 indexed citations
10.
Wagner, Markus, et al.. (1998). Transfection of the type I TGF-β receptor restores TGF-β responsiveness in pancreatic cancer. International Journal of Cancer. 78(2). 255–260. 60 indexed citations
11.
Ishiwata, Toshiyuki, Helmut Friess, Markus W. Büchler, Martha E. Lopez, & Murray Korc. (1998). Characterization of Keratinocyte Growth Factor and Receptor Expression in Human Pancreatic Cancer. American Journal Of Pathology. 153(1). 213–222. 89 indexed citations
12.
Ishiwata, Toshiyuki, Uwe Bergmann, Marko Kornmann, et al.. (1997). Altered Expression of Insulin-like Growth Factor II Receptor in Human Pancreatic Cancer. Pancreas. 15(4). 367–373. 36 indexed citations
13.
Wagner, Markus, Tracy T. Cao, Martha E. Lopez, et al.. (1996). Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. International Journal of Cancer. 68(6). 782–787. 42 indexed citations
14.
Lopez, Martha E., Michael S. Kobrin, Munehiro Yokoyama, et al.. (1996). Single-Strand Conformation Polymorphism Analysis of the Epidermal Growth Factor Receptor at Codon 497. Pancreas. 12(3). 216–220. 3 indexed citations
15.
Baldwin, Rae Lynn, Helmut Frieß, Munehiro Yokoyama, et al.. (1996). Attenuated ALK5 receptor expression in human pancreatic cancer: Correlation with resistance to growth inhibition. International Journal of Cancer. 67(2). 283–288. 94 indexed citations
16.
Descamps, V., et al.. (1996). LacZ gene transfer into tumor cells abrogates tumorigenicity and protects mice against the development of further tumors.. PubMed. 3(3). 212–6. 23 indexed citations
17.
Ebert, Matthias P., Masaaki Yokoyama, Helmut Friess, et al.. (1994). Induction and expression of amphiregulin in human pancreatic cancer.. PubMed. 54(15). 3959–62. 129 indexed citations
18.
Casey, Graham, Yoichiro Yamanaka, Helmut Frieß, et al.. (1993). p53 Mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Letters. 69(3). 151–160. 138 indexed citations
19.
Yamanaka, Yoichiro, et al.. (1993). Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas.. PubMed. 53(20). 4741–4. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M Terada Breakdown of academic impact, for papers by Eva Cubillo Breakdown of academic impact, for papers by Takashi Sugimura Breakdown of academic impact, for papers by Yanli Su Breakdown of academic impact, for papers by Ivan Ischenko Breakdown of academic impact, for papers by Surabhi Dangi‐Garimella Breakdown of academic impact, for papers by Mary Thorncroft Breakdown of academic impact, for papers by Lidia Moserle Breakdown of academic impact, for papers by Maher N. Younes Breakdown of academic impact, for papers by Angela A.G. van Tilborg
Rankless by CCL
2026